D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 46.37 CNY 0.63%
Market Cap: 19.3B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Common Stock
ÂĄ408.2m
CAGR 3-Years
4%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Common Stock
ÂĄ906k
CAGR 3-Years
4%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Common Stock
ÂĄ59k
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Common Stock
ÂĄ1.3B
CAGR 3-Years
43%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Common Stock
ÂĄ6.6B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
27%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Common Stock
ÂĄ2.4B
CAGR 3-Years
14%
CAGR 5-Years
8%
CAGR 10-Years
12%
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.9B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
29.84 CNY
Overvaluation 36%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Common Stock?
Common Stock
408.2m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Common Stock amounts to 408.2m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
-11%

Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 4% over the past three years , -11% over the past five years .

Back to Top